MedTrace Logo

To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets

NCT00913237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Desipramine Hydrochloride 50 mg tablets.

Conditions

Interventions

DRUG

Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)

DRUG

Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)

Sponsors & Collaborators

Principal Investigators

  • Jules Kann, M.D. · Biodecision Laboratories

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1987-07-31
Primary Completion
1987-08-31
Completion
1987-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913237 on ClinicalTrials.gov